Panelists discuss how pharmacists, through frequent patient contact and vigilant observation, are uniquely positioned to identify early signs of tardive dyskinesia, conduct AIMS assessments, monitor treatment efficacy, foster patient trust, and provide crucial education to support timely intervention and improve long-term management outcomes.